Why IMU is a multi multi bagger, page-455

Food for thought .....

when paul hopper was in viralytics (asx vla) the following was roughly the path.....

1 02/03/2017 Viralytics to Present New CAVATAK Clinical Data at AACR ($0.96c)
2 31/10/2017 Viralytics to Present at 2017 SITC (Society for Immunotherapy of Cancer) Annual Meeting
3 13/11/2017 New Data at SITC Meeting. Further Studies Announced
4 05/01/2018 $29.6m Equity Placement (13%) to Lepu Medical Group of China
5 08/01/2018 JP Morgan Healthcare conference, new investor presentation ($0.80c)
6 21/02/2018 MSD and Viralytics Announce Acquisition Agreement ($0.61c -> $1.62c)
7 11/04/2018 New CAVATAK Data at International Oncolytic Virus Conference
8 20/04/2018 Court approves convening of scheme meeting
9 05/06/2018 Suspension from Official Quotation at close ($1.74c)
10 20/06/2018 Implementation of Scheme of Arrangement

(Roughly 15 months)
The above are the major price sensitive announcements leading towards the agreement and final removal from ASX listing.
Having read, read and reread about IMU, big pharma acquisitions, cost of drug development, I cannot go past a scenario similar to the above (T/O, acquisition).


https://www.**promotion blocked**.au/tickers/asx-vla/ check for graph!!!!